Open access
Jul 2026
Dual-targeting CD73/PD-L1 bifunctional inhibitor: a promising cancer immunotherapy strategy
CP-1 exhibits balanced, dual-nanomolar inhibitory activity against PD-L1 and CD73 and displays potent immunomodulatory effects at the cellular level and serves as a promising lead candidate for developing novel bifunctional agents to advance tumor immunotherapy.
Jing-Jing Du, Sen Wu, Shiyun Cheng et al.
· Frontiers in Immunology · 0 citations